BM
DNLI icon

Bridger Management’s Denali Therapeutics DNLI Stock Holding History

Bridger Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-312,500
Closed -$5.05M – 39
2018
Q1 		$5.05M Hold
312,500
– – 0.31% 37
2017
Q4 		$4.89M Buy
+312,500
New +$5.62M 0.32% 33

Other funds holding DNLI

CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Bridger Management's DNLI Position: Q2 2018 in Review

Bridger Management sold out of Denali Therapeutics (DNLI) in Q2 2018, closing a stake of 312,500 shares — an estimated $5.05M sold.

Bridger Management first reported a position in DNLI in Q4 2017 and held it in 2 quarters. The position peaked at $5.05M in Q1 2018. 67 funds tracked by Wall St. Rank hold DNLI as of Q2 2018.

  • Bridger Management reported no remaining Denali Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Bridger Management sold 312,500 Denali Therapeutics shares in Q2 2018, an estimated $5.05M.
  • Bridger Management first reported a position in Denali Therapeutics in Q4 2017 and held it in 2 quarters.
  • Bridger Management's Denali Therapeutics position peaked at $5.05M in Q1 2018.
  • 67 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2018.

Based on Bridger Management's 13F filing for Q2 2018, filed 14 Aug 2018.